Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s First Medical Devices Innovation Base To Set Up In Chongqing

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Science and Technology has reached an agreement with Chongqing municipal government to set up an independent national innovation industry base for medical devices. The facility will focus on common problems in the industry by building up a public service platform for fast innovation design, new technology development and application, as well as experimental technology standards. It will also conduct industry, national and international research. After five years, the base is targeted to achieve breakthrough in industrialized core technologies for 50 projects and realize a production value of RMB 50 billion. Chongqing has an edge in independent R&D and innovation within the digital health sector, having developed the world's first high-intensity focused ultrasound tumor therapy system and Asia's first gastrointestinal capsule endoscopy. (Click here for more - Chinese Language)

You may also be interested in...

Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

EMA Set To Discuss Safety Of Ranitidine

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

Alvogen Aims To Be First On EU Pazopanib

Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts